Accéder au contenu
Merck

Acetylation of core histones in response to HDAC inhibitors is diminished in mitotic HeLa cells.

Experimental cell research (2010-05-11)
Jason S Patzlaff, Edith Terrenoire, Bryan M Turner, William C Earnshaw, James R Paulson
RÉSUMÉ

Histone acetylation is a key modification that regulates chromatin accessibility. Here we show that treatment with butyrate or other histone deacetylase (HDAC) inhibitors does not induce histone hyperacetylation in metaphase-arrested HeLa cells. When compared to similarly treated interphase cells, acetylation levels are significantly decreased in all four core histones and at all individual sites examined. However, the extent of the decrease varies, ranging from only slight reduction at H3K23 and H4K12 to no acetylation at H3K27 and barely detectable acetylation at H4K16. Our results show that the bulk effect is not due to increased or butyrate-insensitive HDAC activity, though these factors may play a role with some individual sites. We conclude that the lack of histone acetylation during mitosis is primarily due to changes in histone acetyltransferases (HATs) or changes in chromatin. The effects of protein phosphatase inhibitors on histone acetylation in cell lysates suggest that the reduced ability of histones to become acetylated in mitotic cells depends on protein phosphorylation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-acétyl-histone H3 (Lys9), serum, Upstate®
Sigma-Aldrich
Anticorps anti-acétyl-histone H3 (Lys23), serum, Upstate®
Sigma-Aldrich
Anticorps anti-histone H4, pan, clone 62-141-13, monoclonal de lapin, clone 62-141-13, Upstate®, from rabbit
Sigma-Aldrich
Anticorps anti-acétyl-histone H3 (Lys18), serum, Upstate®
Sigma-Aldrich
Anti-acetyl-Histone H4 (Lys12) Antibody, serum, Upstate®
Sigma-Aldrich
Anti-acetyl-Histone H4 (Lys8) Antibody, serum, Upstate®